Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer
Highlights
- Synergistic antitumor effects from Olvi-Vec and cisplatin were demonstrated in a mouse model of PROC.
-
We studied changes in the TME following Olvi-Vec treatment in patients with PRROC.
- IHC analysis showed an influx of CD4+ and CD8+ TILs in post-Olvi-Vec-infected tumor tissues.
- Olvi-Vec-primed immunochemotherapy resulted in improved PFS compared to the last line of therapy in PRROC.
Click here to read the full publication.
